Home
About
Overview
Sharing Data
ORCID
Help
History (66)
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
Overcoming Barriers to Tobacco Cessation and Lung Cancer Screening among Racial and Ethnic Minority Groups and Underserved Patients in Academic Centers and Community Network Sites: The City of Hope Experience.
Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial.
Synergistic efficacy of RLIP inhibition and 2'-hydroxyflavanone against DMBA-induced mammary carcinogenesis in SENCAR mice.
An E3 ubiquitin ligase: c-Cbl: a new therapeutic target of lung cancer.
See All 66 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
An E3 ubiquitin ligase: c-Cbl: a new therapeutic target of lung cancer.
An E3 ubiquitin ligase: c-Cbl: a new therapeutic target of lung cancer. Cancer. 2011 Dec 01; 117(23):5344-50.
View in:
PubMed
subject areas
Animals
Cell Line, Tumor
Cell Movement
Cell Proliferation
Female
Humans
Lung Neoplasms
Mice
Mice, Inbred BALB C
Proto-Oncogene Proteins c-cbl
Transfection
authors with profiles
Ravi Salgia